{
    "medicine_id": "1b22997de2324f814e320bb2b9ed9a2c9e8c862c",
    "platform_id": "DB05311",
    "metadata": {
        "name": "Kalbitor 10 mg 1mL Injection solution",
        "composition": "10 mg 1mL Ecallantide",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the symptomatic treatment of acute attacks of hereditary angioedema HAE in patients 12 years of age and older FDA Label",
            "contraindications": {
                "disease": "While there have been no reports of overdose with ecallantide patients with hereditary angioedema have received single doses up to 90 mg intravenously without evidence of dose related toxicity FDA Label There are no animal or human studies to assess the carcinogenic or mutagenic potential of ecallantide FDA Label In rats receiving subcutaneous doses up to 25 mg kg day there were no observable effects on fertility reproductive performance FDA Label An approximate lethal dose was identified as 25 mg kg intravenously in rats and 5 mg kg intravenously in rabbits L1458",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Intravenous administration of ecallantide doses 20 mg m 2 resulted in prolongation of activated partial thromboplastin time aPTT without an indication of bleeding Ecallantide administration has been associated with instances of arrhythmia In a clinical trial of patients experiencing acute attacks of hereditary angioedema HAE intravenous administration of ecallantide demonstrated a significant improvement in symptoms affecting the oropharynx abdomen gastrointestinal tract and limbs within 4 hours post administration compared to placebo A32016 A substantial decrease in the severity and duration of attacks was also observed in patients with moderate to severe HAE attacks A32014 In clinical trials ecallantide had no significant effect on the QTc interval heart rate or any other components of the ECG FDA Label",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}